The first subject has been dosed in a phase 1b trial of the primary open-angle glaucoma treatment candidate AKB-9778, according to a press release from Aerpio Pharmaceuticals.
AKB-9778 binds to and inhibits vascular endothelial protein tyrosine phosphatase, a negative regulator of Tie2, the release said.
The multiple-ascending dose, double-masked trial will include four cohorts of 12 subjects who will receive increasing daily doses of topical AKB-9778 or placebo for 7 days. Ocular safety and tolerability are the primary endpoints of the trial.
“We have recently shown in animal models that